UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, DC 20549


                                   FORM 10-QSB



[X]   Quarterly Report pursuant to Section 13 or 15(d) of the Securities
      Exchange Act of 1934

      For the quarterly period ended  August 31, 2006
                                      -----------------

[ ]   Transition Report pursuant to 13 or 15(d) of the Securities Exchange
      Act of 1934

      For the transition period                  to
                               ------------------   --------------------

      Commission File Number    333-107179
                            -----------------


                             XPENTION GENETICS, INC.
    ------------------------------------------------------------------------
       (Exact name of small Business Issuer as specified in its charter)


                               BAYVIEW CORPORATION
    ------------------------------------------------------------------------
     (Former name, former address and former fiscal year, if changed since
                                 last report)



          Nevada                                         98-0380519
---------------------------------             --------------------------------
(State or other jurisdiction of              (IRS Employer Identification No.)
 incorporation or organization)

10965 Elizabeth Drive
Conifer, CO                                               80433
----------------------------------------      --------------------------------
(Address of principal executive offices)           (Postal or Zip Code)


Issuer's telephone number, including area code:        (303) 908-4900
                                                ------------------------------

<PAGE>

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Securities  Exchange  Act of 1934  during the  preceding  12
months (or for such  shorter  period  that the issuer was  required to file such
reports),  and (2) has been subject to such filing  requirements for the past 90
days [X] Yes [ ] No

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).        [_] Yes         [X] No

State the number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date:  57,625,833 shares of $0.001 par value
common stock outstanding as of October 24, 2006.

Transitional Small Business Disclosure Format (Check one):   [_] Yes     [X] No


<PAGE>

                          PART I FINANCIAL INFORMATION

Item 1.  Financial Statements

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                                          BALANCE SHEET
                                         AUGUST 31, 2006
                                           (Unaudited)

ASSETS
<S>                                                                       <C>
Current assets
Cash and cash equivalents                                                                 $ -
                                                                          ====================


LIABILITIES

Current liabilities
Accounts payable and accrued expenses                                               $ 315,798
Advance from shareholder                                                                1,500
   Bank overdraft                                                                       1,244
   Note payable                                                                       100,000
                                                                          --------------------
    Total current liabilities                                                         418,542
                                                                          --------------------


STOCKHOLDERS' (DEFICIT)

Preferred stock, $0.001 par value, 10,000,000 shares authorized,
none issued or outstanding                                                                  -
Common stock, $0.001 par value, 100,000,000 shares authorized,
 57,625,833 shares issued and outstanding                                              57,626
Additional paid-in capital                                                            711,474
   (Deficit) accumulated during the development stage                              (1,187,642)
                                                                          --------------------
                                                                                     (418,542)
                                                                          --------------------

                                                                                          $ -
                                                                          ====================
</TABLE>




 The accompanying footnotes are an integral part of these financial statements.

                                      F-1

<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                                    STATEMENTS OF OPERATIONS
                   THREE MONTHS ENDED AUGUST 31, 2006 AND 2005 (RESTATED) AND
                         OCTOBER 13, 2004 (INCEPTION) TO AUGUST 31, 2006
                                           (Unaudited)



                                                     Three Months Ended August 31,                  October 13, 2004
                                                      2006                    2005                     (Inception)
                                                                           (Restated)              to August 31, 2006
                                              ---------------------    -------------------    ------------------------------
<S>                                           <C>                      <C>                    <C>
Revenues                                               $ -                     $ -        -                $ --
                                              ---------------------    -------------------    ------------------------------

Expenses
     Research and development                               13,140                 78,760                           467,011
     Stock compensation                                          -                 92,250                           369,000
 General and administrative                                 40,148                 54,600                           342,080
                                              ---------------------    -------------------    ------------------------------
                                                            53,288                225,610                         1,178,091
                                              ---------------------    -------------------    ------------------------------

Operating (loss)                                           (53,288)              (225,610)                       (1,178,091)
                                              ---------------------    -------------------    ------------------------------

Other income (expense)
Interest expense                                            (1,400)                (1,250)                           (9,551)
                                              ---------------------    -------------------    ------------------------------

Net (loss)                                                 (54,688)              (226,860)                       (1,187,642)
                                              ---------------------    -------------------    ------------------------------

Comprehensive income:
Currency translation gain                                        -                      -                                 -

Comprehensive (loss)                                     $ (54,688)            $ (226,860)                     $ (1,187,642)
                                              =====================    ===================    ==============================

Basic and diluted:
  (Loss) per share                                         $ (0.00)               $ (0.00)
                                              =====================    ===================

  Weighted average shares outstanding                   57,625,833             57,434,529
                                              =====================    ===================

 The accompanying footnotes are an integral part of these financial statements.
</TABLE>

                                      F-2

<PAGE>

<TABLE>
<CAPTION>


                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                                    STATEMENTS OF CASH FLOWS
                   THREE MONTHS ENDED AUGUST 31, 2006 AND 2005 (RESTATED) AND
                         OCTOBER 13, 2004 (INCEPTION) TO AUGUST 31, 2006
                                           (Unaudited)

                                                           Three Months Ended August 31,             October 13, 2004
                                                              2006                2005                  (Inception)
                                                                               (Restated)           to August 31, 2006
                                                        -----------------    ----------------    --------------------------
<S>                                                     <C>                  <C>                 <C>

Cash Flows From Operating Activities
                                                        -----------------    ----------------    --------------------------
Cash flows (used in) operating activities                        (21,973)           (116,670)                     (502,844)
                                                        -----------------    ----------------    --------------------------


Cash Flows From Investing Activities                                   -                   -                             -
                                                        -----------------    ----------------    --------------------------
Cash flows provided by (used in) investing activities                  -                   -                             -
                                                        -----------------    ----------------    --------------------------


Cash Flows From Financing Activities
   Proceeds from note payable                                          -                   -                       100,000
   Bank overdraft                                                  1,244                   -                         1,244
   Advances from shareholder                                       1,500                   -                         1,500
Proceeds from issuance of common stock                                 -             400,000                       400,100
                                                        -----------------    ----------------    --------------------------
Cash flows provided by financing activities                        2,744             400,000                       502,844
                                                        -----------------    ----------------    --------------------------

Increase (decrease) in cash                                      (19,229)            283,330                             -

Cash, beginning of period                                         19,229              15,422                             -
                                                        -----------------    ----------------    --------------------------

Cash, end of period                                      $             -      $      298,752     $                       -
                                                        =================    ================    ==========================


Supplemental cash flow information
  Income taxes paid                                                  $ -                 $ -                           $ -
                                                        =================    ================    ==========================
  Interest expense paid                                              $ -                 $ -                       $ 6,493
                                                        =================    ================    ==========================
</TABLE>


 The accompanying footnotes are an integral part of these financial statements.

                                      F-3

<PAGE>

<TABLE>
<CAPTION>

                                     XPENTION GENETICS, INC.
                                  (A Development Stage Company)
                              STATEMENT OF STOCKHOLDERS' (DEFICIT)
                         OCTOBER 13, 2004 (INCEPTION) TO AUGUST 31, 2006
                                           (Unaudited)
                                                                                              (Deficit)
                                                                                             Accumulated
                                                   Common Stock           Additional         During the
                                                Shares       Amount    Paid in Capital    Development Stage       Total
                                            --------------------------------------------------------------------------------
<S>                                         <C>              <C>         <C>                   <C>               <C>
October 13, 2004 (Inception)                             -         $ -              $ -                   $ -           $ -

Stock issued for cash at inception                  13,000         100                -                     -           100

Recapitalization                                56,829,500      56,743          (56,743)                    -             -

Net (loss)                                               -           -                -              (156,750)     (156,750)
                                            --------------------------------------------------------------------------------

Balance, May 31, 2005                           56,842,500      56,843          (56,743)             (156,750)     (156,650)

Common stock issued for cash                       333,333         333          399,667                     -       400,000

Common stock issued for services                   450,000         450          368,550                     -       369,000

Net (loss)                                               -           -                -              (976,204)     (976,204)
                                            --------------------------------------------------------------------------------

Balance May 31,  2006                           57,625,833      57,626          711,474            (1,132,954)     (363,854)
                                            --------------------------------------------------------------------------------

Net (loss)                                               -           -                -               (54,688)      (54,688)

Balance August 31,  2006                        57,625,833    $ 57,626        $ 711,474          $ (1,187,642)   $ (418,542)
                                            --------------------------------------------------------------------------------



         The accompanying footnotes are an integral part of these financial statements.
</TABLE>


                                      F-4

<PAGE>

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Financial Statements

The accompanying unaudited financial statements of Xpention Genetics,  Inc. have
been prepared in accordance with generally  accepted  accounting  principles for
interim financial  information and with the instructions to Form 10-QSB and Rule
10-01 of  Regulation  S-X.  The  financial  statements  reflect all  adjustments
consisting of normal recurring adjustments, which, in the opinion of management,
are  necessary  for a fair  presentation  of the results for the periods  shown.
Accordingly,  they do not include all of the information and footnotes  required
by generally accepted accounting principles for complete financial statements.

These  financial  statements  should  be read in  conjunction  with the  audited
financial  statements and footnotes  included  thereto for the fiscal year ended
May 31,  2006,  for  Xpention  Genetics,  Inc. on Form 10KSB,  as filed with the
Securities and Exchange Commission.

The preparation of financial  statements in conformity  with generally  accepted
accounting principles requires management to make estimates and assumptions that
affect  the  reported  amounts  of assets  and  liabilities  and  disclosure  of
contingent  assets and  liabilities at the date of the financial  statements and
that effect the reported  amounts of revenues and expenses  during the reporting
period. Actual results could differ from those estimates.

Organization

Xpention Genetics,  Inc. (the Company) was incorporated in the State of Colorado
on October 13, 2004, and has been in the development  stage since its inception.
In March 2005, the Company  entered the  biotechnology  industry to develop both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers. In March 2005, the Company changed its name to Xpention Genetics,
Inc. The Company has been in the  development  stage since its formation and has
not yet  realized  any  revenues  from its planned  operations.  The Company has
chosen May 31 as its fiscal year-end.

Bayview  Corporation was  incorporated  in the State of Nevada,  on September 5,
2002. From inception until February 28, 2005, the Company was primarily  engaged
in the acquisition and exploration of mining properties.  Subsequent to February
28,  2005,  the Company  entered  the  biotechnology  industry  to develop  both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers.

                                      F-5

<PAGE>

During March 2005,  Bayview issued  14,300,000 shares of its common stock to the
shareholders  of the  Xpention,  Inc.  in  exchange  for all of the  issued  and
outstanding  common  shares of  Xpention  pursuant to an  Agreement  and Plan of
Reorganization.  In addition,  concurrent  with the exchange of shares,  Bayview
changed its name to Xpention Genetics, Inc.

This   acquisition  of  Xpention,   the  accounting   acquirer,   by  Bayview  a
non-operating  entity,  is considered in substance a capital  transaction by the
issuance of  14,300,000  shares of common stock by Bayview for all of the issued
and  outstanding  common shares of Xpention,  and was accounted for as a reverse
acquisition,  and no goodwill or other intangible assets were recorded.  On this
basis,  the historical  financial  statements as of and prior to the acquisition
date represent the operations of Xpention.

Net (Loss) Per Common Share

The Company  follows SFAS 128,  "Earnings Per Share".  Basic earnings (loss) per
common share  calculations  are  determined by dividing net income (loss) by the
weighted average number of shares of common stock  outstanding  during the year.
Diluted earnings (loss) per common share calculations are determined by dividing
net income (loss) by the weighted  average  number of common shares and dilutive
common  share  equivalents  outstanding.   During  the  periods  when  they  are
anti-dilutive,  common  stock  equivalents,  if any, are not  considered  in the
computation.

NOTE 2. NOTE PAYABLE

In November  2004,  an  unrelated  third party lent the Company  $100,000 to pay
operating  expenses  pursuant to a note.  This note is due on the earlier of (i)
the Company  successfully  receiving financing in excess of $1,000,000;  or (ii)
December 31, 2006. Interest accrues at a rate of 5.0% per annum.

NOTE 3. COMMITMENTS

On February 17, 2005,  the  Company's  wholly-owned  subsidiary  Xpention,  Inc.
entered into a License and Technology Licensing Agreement with the University of
Texas  M.D.  Anderson  Cancer Center  ("UTMDACC") to  commercialize   technology
developed for cancer  detection in animals and humans.  The Company paid $50,000
for the  license  which was  expensed  during the year ended May 31,  2005.  The
Agreement calls for a 5.5% royalty to be paid to UTMDACC on the sale of products
utilizing the licensed technology.  In addition payments of $50,000 each are due
upon the  first  sales to both the  veterinary  market  and  human  market.  The
Agreement expires in February 2020.

On July 21, 2005,  the Company  entered into a Research  Agreement with Colorado
State  University  ("CSU")  for  research  activities  in  connection  with  the
development of the p65 immunological  test for canines in which CSU will provide
canine blood and tissue  specimens  for use in clinical  trials.  The  agreement
terminated on July 1, 2006, and requires payments to CSU totaling $17,520.

On November 2, 2005,  the Company  amended its Research  Agreement with Colorado
State  University.  The  amendment  calls for CSU to  collect  additional  blood
samples for use by the Company in development of a canine cancer  detection test
and extends the  agreement  to November 1, 2006.  The Company  will pay Colorado
State  University an additional  $15,330 for the work performed  pursuant to the
amendment.

On December 1, 2005,  the Company  entered  into a Research  Agreement  with The
University of Texas Health  Science  Center at San Antonio  ("UTHSCSA")  whereby
UTHSCSA  agreed  to  perform   research   activities   for   development  of  an
immunological  test for canines.  This agreement replaces the Research Agreement
the Company  entered into with AMC Cancer  Research Center in May 2005 which has
been  relinquished by AMC. The agreement with UTHSCSA will permit the Company to
continue its  collaboration  with Dr.  Margaret  Hanausek who accepted a faculty
position at UTHSCSA.  The Company will pay $64,306 to UTHSCSA for work performed
pursuant to the Agreement.

                                      F-6

<PAGE>

Item 2. Management's Discussion and Analysis or Plan of Operation

FORWARD LOOKING STATEMENTS

This quarterly report contains forward-looking statements that involve risks and
uncertainties.  We use words such as anticipate,  believe, plan, expect, future,
intend and similar expressions to identify such forward-looking  statements. You
should not place too much  reliance  on these  forward-looking  statements.  Our
actual results are likely to differ  materially from those  anticipated in these
forward-looking  statements  for many  reasons,  including the risks faced by us
described in this Risk Factors section and elsewhere in this annual report.

Plan of Operation

The Company, through its wholly-owned subsidiary,  holds the exclusive worldwide
license for  patented  technology  for the  detection of cancer based on a tumor
marker known as p65 which has been  demonstrated  to have elevated levels in the
blood of canine and human  cancer  conditions.  p65 is  believed to be a protein
required in the early  development  of numerous  cancers and appears  from early
research  to provide a strong  indication  of tumor  growth in both  canines and
humans.  It also appears to have a direct  correlation to tumor size/mass making
it a promising  marker for both early  detection of malignant tumor formation as
well as a useful tool for  monitoring  therapy  and  remission.  Initially,  the
Company plans to develop an immunological  test as well as a molecular assay for
detection  of  cancer  in  canines.  The  Company  also  plans to  develop  both
immunological  and  molecular  tests for  detection of human  cancers as well as
therapeutic treatments and vaccines.

During the interim  period  ended  August 31, 2006,  the Company  continued  its
research  activities  for the  development  of an  immunological  canine  cancer
detection  test as well as a  molecular  assay for  detection  of cancer in both
canines and humans,  all of which are being conducted by third parties on behalf
of the company.  The Company  also  continues  to evaluate  various  options for
commercialization  of its  products;  however,  it is not  anticipated  that the
Company will generate any revenues from commercialization of its products during
FY 2006.

Results of Operations for the Period Ending August 31, 2006

The Company  did not earn any  revenues  during the  three-month  period  ending
August 31, 2006. For the three-month  period ending August 31, 2006, the Company
incurred expenses totaling $53,288 including  research and development  expenses
of $13,140 and  general and  administrative  expenses of $40,148  plus  interest
expense of $1,400 for a total loss  during the period of  $54,688.  The  Company
used its cash  reserves  plus the  proceeds  of  shareholder  advances  to cover
research  and  development  expenses as well as  administrative  expenses of the
Company  during the period.  For the  three-month  period  ended August 31, 2005
(Restated),  the Company incurred  expenses of $225,610  including  research and
development expenses of $78,760,  general and administrative expenses of $54,600
and stock  compensation  expense  (non-cash) of $92,250 plus interest expense of
$1,250 for a total loss during the period of  $226,860.  The decrease in the net
loss from  $226,860 for the  three-month  period ending August 31, 2005 to a net
loss of $54,688 for the three-month period ending August 31, 2006 is primarily a
result of decreases in operating  expenses  including  elimination  of the stock
compensation  expense  (non-cash)  of $92,250  arising from the  completion of a
consulting  agreement  during the  period  ending May 31,  2006,  a decrease  in
research and  development  expenditures of $65,620 during the period compared to
the prior  period  and a decrease  in general  and  administrative  expenses  of
$14,452 during the period  compared to the prior period.  Since  inception,  the
Company has not  generated  any  revenues  and has  incurred  expenses  totaling
$1,178,091 plus interest  expense of $ 9,551 for a total loss since inception of
$1,187,642.

The Company had no cash on hand at 8/31/2006  and  accounts  payable and accrued
liabilities  totaling  $315,798,  bank  overdraft  of $1,244 and note payable of
$100,000 at  8/31/2006.  The Company's  ability to pay its accounts  payable and
accrued  expenses and repay the note  payable is  dependent  upon receipt of new
funding from shareholder advances, private placements or bridge financing.

<PAGE>

Item 3.  Controls and Procedures

Evalution of Disclosure Controls

A review and evaluation was performed by the Company's management, including the
Company's Chief Executive  Officer (the "CEO") and Chief Financial  Officer (the
"CFO"),  of the  effectiveness  of the design  and  operation  of the  Company's
disclosure  controls  and  procedures  as of a date  within 90 days prior to the
filing of this quarterly  report.  Based on that review and evaluation,  the CEO
and CFO have  concluded  that the  Company's  current  disclosure  controls  and
procedures,  as designed and  implemented,  were  effective.  There have been no
significant changes in the Company's internal controls subsequent to the date of
their evaluation.  There were no significant  material weaknesses  identified in
the course of such review and evaluation and, therefore,  no corrective measures
were taken by the Company.

Disclosure  controls  are  controls  and other  procedures  that are designed to
ensure that  information  that is  required  to  disclose  in the reports  filed
pursuant  to  the  Securities  Exchange  Act of  1934  is  recorded,  processed,
summarized and reported.



                           PART II- OTHER INFORMATION

Item 1.  Legal Proceedings

The Company is not a party to any pending legal proceeding.  Current  management
is not aware of any threatened litigation, claims or assessments.


Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

The Company did not issue any  securities  during the quarter  ended  August 31,
2006.

<PAGE>

Item 3. Defaults Upon Senior Securities

         None.


Item 4. Submission of Matters to a Vote of Security Holders

         None.


Item 5. Other Information

         None.


Item 6. Exhibits and Reports on Form 8-K

        A.  Exhibits

            31 Certification  pursuant  to 18 U.S.C.  Section  1350,  as adopted
               pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

            32 Certification  pursuant  to 18 U.S.C.  Section  1350,  as adopted
               pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        B.  Reports on Form 8-K

            None




<PAGE>

                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Dated:  October 23, 2006

                                        Xpention Genetics, Inc.

                                        /s/ David Kittrell
                                        ------------------------------
                                        David Kittrell, President